At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 411 enrolled
Drug / intervention
Elobixibat 10 mgdrug
Likely dose
Elobixibat 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-label, Safety and Tolerability Extension Trial of 5 mg and 10 mg Elobixibat Daily in the Treatment of Chronic Idiopathic Constipation
In Brief
A Phase 3 clinical trial evaluating Elobixibat 10 mg for Chronic Idiopathic Constipation. Completed, enrolled 411 participants across 62 sites in 10 countries.
Detailed Summary
Safety and Tolerability Extension Trial for Patients with Chronic Idiopathic Constipation (CIC)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Idiopathic Constipation
CountriesBelgium, Canada, Czechia, Hungary, Poland, Slovakia, South Africa, Sweden, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJul 2013
Enrollment StartSep 2013
Primary CompletionMay 2015
TodayJul 2026
First PostedJul 10, 2013
Enrollment StartSep 1, 2013
Primary CompletionMay 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 13.0 years ago
Interventions
Elobixibat 10 mgdrug
10 mg Elobixibat daily, with possibility for dose adjustment to 5 mg daily.